International: +1-347-960-6455
Japanese Encephalitis (JE) Therapeutics Pipeline to Witness Remarkable Growth due to Adoption of Strategic Collaboration Approach by Drug Developers

According to a new research report Japanese Encephalitis (JE) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, JE therapeutics currently exhibits a proliferating pipeline with 10+ therapeutic candidates.

JE Therapeutics Pipeline Insights

JE is a viral infection caused by the bite of Culex tritaeniorhynchus mosquito. The prevention from the mosquito bites is the key preventive measure for the disease. Most of the individuals suffering from JE do not show clinical symptoms; whereas, the individuals in whom the symptoms develop show signs of neurologic symptoms, weakness, and movement disorders after 10–15 days.

As per the current scenario, there is no marketed products available for the primary treatment of JE. Symptomatic treatment and vaccines for prior immunizations are available to prevent the disease from infecting the people.

Insights into Pipeline Segments

According to the research findings, majority of pipeline drug candidates are being developed to be administered by intravenous route. It has been observed that intravenous route of medications is dependable and possesses reproducible effects. Moreover, the entire administered dose reaches the systemic circulation immediately increasing the bioavailability of drug.

Strategic Collaborations are Expected to Drive JE Pipeline

Companies that are involved in developing therapeutics for JE have shown active participation in strategic collaborations to boost up the development of their candidates for JE. For instance, in November 2015, Intercell USA Inc. entered into distribution and marketing services agreement with VaxServe Inc., a Sanofi Pasteur company. Under the terms of the agreement, VaxServe Inc. performed marketing and promotional services and distributed Valneva’s Japanese encephalitis vaccine in the U.S.

Browse Detailed Report at:

Technical Advancement to Accelerate the Development Process of JE Therapeutics

Technical advancements in the JE therapeutics development are expected to trigger the growth of the JE therapeutics market. For instance, Intercell’s Antigen Identification Program identifies novel antigens from a variety of pathogens, which are believed to induce the strongest response from the human immune system; thus, providing a viable basis for the further potential development of novel and more powerful prophylactic and therapeutic vaccines and antibody treatments.

Indian Immunologicals Ltd., Abivax SA, Ennaid Therapeutics LLC, Biological E. Limited, Bharat Biotech Ltd., Valneva Scotland Ltd., Sanofi-aventis Groupe, and Kineta Inc. are some of the key players involved in the development of therapeutic drugs indicated for the treatment of JE.

JE Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of JE. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the JE therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to JE.